By following this link you'll go directly to the site map at the end of each page
IT (EN)
   Person in charge: Barbara Ensoli
You're in:
 Recently updated

1document

State of Art of Anti-HIV/AIDS Vaccine Clinical Trials - update on 1/04/2014

State of Art of Anti-HIV/AIDS Vaccine Clinical Trials based on the recombinant biologically active HIV-1 Tat protein sponsored by ISS updated on april 1st 2014.

Published 11-28-2013 in Vaccines against HIV/AIDS , last update 04-01-2014 More...

Share: 

About us

Our aim is fighting HIV/AIDS and associated syndromes by developing vaccines and new therapeutic approaches based on studies of the pathogenic mechanisms of HIV infection and progression. The NAC organization reflects the aim to put into effect a “translational” research.

Published 03-04-2013 in About us , last update 03-28-2014 More...

Share: 

1document

BARBARA ENSOLI WAS APPOINTED AMONG THE NEW MEMBERS OF THE ERC

Barbara Ensoli, Director of the National AIDS Center- ISS, was appointed among the new members of the European Research Council (European Research Council,...

Published 11-14-2012 in Highlights , last update 03-28-2014 More...

Share: 

UNRAVELING THE MECHANISMS REQUIRED FOR HIV VACCINE PROTECTION

As published today in PLoS ONE, by binding the Envelope protein present on virus particles, HIV Tat forms a new virus entry complex that favours the infection of cells present at the portals of virus entry (i.e. dendritic cells, macrophages). These cells represent also key HIV reservoirs that ensure the persistence of HIV in the host even under an "effective" antiretroviral treatment. By binding Env, Tat renders ineffective anti-Env antibodies at blocking virus entry in target cells. Thus, both anti-Tat and anti-Env antibodies are required for efficient HIV neutralization and should be both present to block HIV acquisition and spreading, but also the persistent infection and residual disease which is still present under antiretroviral therapy.

"This finding...

Published 11-14-2012 in Highlights , last update 03-28-2014 More...

Share: 

3documents

LAUNCH OF THE PHASE I TRIAL OF THE SECOND GENERATION OF PREVENTIVE VACCINE AGAINST HIV INFECTION BASED ON THE ASSOCIATION OF TAT AND ENV PROTEINS OF HIV-1 IN HEALTHY ADULT VOLUNTEERS

The National Center of the Istituto Superiore di Sanità launches the first phase of clinical testing of preventive HIV vaccine (study ISS P-002) based on a vaccine that combines the Tat protein, which is already advanced to therapeutic phase II trials in Italy and South Africa, and the Env protein,supplied by Novartis as part of a collaboration in the AVIP European project .
Tat and Env proteins have already been tested individually in clinical trials in humans and both were found to be safe and well tolerated, while to date the combination of the two products has been evaluated only in animal models where it has proved to be safe, well tolerated and capable of preventing HIV infection. The new study ISS P-002, involves 3 prominent clinical...

Published 06-15-2011 in Highlights , last update 03-28-2014 More...

Share: 

Legal information


© - Istituto Superiore di Sanità Viale Regina Elena 299 - 00161 - Roma (I)
Partita I.V.A. 03657731000 - C.F. 80211730587 - Legal information

ISS Home